Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering

INTERPACE BIOSCIENCES, INC.

Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.
Cash collections $10.4M (2nd consecutive record quarter); DSO down 48% YoY to 59 days; cash $3.2M at Sep 30.
Entered $7.5M Comerica revolver (matures Sep 2023) and $8M BroadOak term loan to repay private equity bridge loans.
Proposed $30M rights offering (backstopped by 3K Limited Partnership) to fund growth; goal $100M revenue run rate by 2023.
Expanded payor contracts: 54 commercial payors for thyroid tests; two new patents granted for ThyraMIR and PancraGEN technologies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.